Resmetirom tablets (Rezdiffra)

The selected label recommends the same dosage in mild, moderate and severe renal impairment as in normal renal function. This does not remove the separate body-weight and drug-interaction requirements or establish a dialysis-specific regimen.

Section 8.6 recommends the same dosage for mild, moderate and severe renal impairment. Section 12.3 now includes a severe-impairment study using CKD-EPI eGFR <30 mL/min/1.73 m2; its mild/moderate analysis uses MDRD. Preserve those method differences. The renal statement does not remove actual-body-weight dosing, CYP2C8 interaction modifications, statin limits or hepatic restrictions. The selected sections establish no separate dialysis regimen. This dated recheck supplements the existing local record; it is not a claim that the earlier local dose was wrong.

This March 2024 RX mirror recommends the same dosage in mild or moderate renal impairment. Its population analysis covers MDRD eGFR 30-89 mL/min/1.73 m2 and says severe impairment below 30 was not studied. This is dated source wording, not the current official severe-renal conclusion. The separately displayed July 2026 DailyMed label includes severe-impairment data and the same recommended dosage across mild, moderate and severe impairment.